NDAORALTABLET
Approved
Sep 2023
Lifecycle
Growth
Competitive Pressure
0/100
Clinical Trials
20
Data completeness
4/8 — Partial
Drug data last refreshed 20h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
OJJAARA (momelotinib) is an oral small-molecule JAK inhibitor approved by the FDA on September 15, 2023, and developed by GSK. The drug is indicated for multiple myeloproliferative neoplasms including myelofibrosis, polycythemia vera, and essential thrombocythemia, as well as myelodysplastic syndromes and select solid tumors (non-small cell lung cancer and pancreatic ductal adenocarcinoma). Momelotinib works by inhibiting JAK1/JAK2 signaling pathways that drive abnormal cell proliferation and inflammatory cytokine production in these hematologic malignancies.
$0.0BPart D
14.6 years to LOEMechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (20)
Bomedemstat (IMG-7289) in Combination With Momelotinib in Patients With Myelofibrosis
Started Nov 2026
40 enrolled
Myelofibrosis
Comparing Momelotinib and Ruxolitinib in People With Untreated Myelofibrosis and Low Blood Cell Counts
Started Aug 2026
268 enrolled
MyelofibrosisMyelofibrosis (MF)
Momelotinib in Combination With Hypomethylating Agent for Chronic Phase Myelodysplastic Syndromes/Myeloproliferative Overlap Neoplasms and Chronic Neutrophilic Leukemia
Started Mar 2026
18 enrolled
Chronic Myelomonocytic LeukemiaMyelodysplastic SyndromesMyeloproliferative Overlap Neoplasms+1 more
Momelotinib During and After HCT in Myelofibrosis
Started Feb 2026
28 enrolled
MyelofibrosisHematopoietic Cell Transplantation (HCT)
Momelotinib in VEXAS Syndrome
Started Nov 2025
57 enrolled
VEXAS SyndomeMyelo Dysplastic Syndrome
Worked on OJJAARA at GSK? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.